ATE336239T1 - Neue fettsäureanaloge zur behandlung des bluthochdrucks - Google Patents

Neue fettsäureanaloge zur behandlung des bluthochdrucks

Info

Publication number
ATE336239T1
ATE336239T1 AT02024616T AT02024616T ATE336239T1 AT E336239 T1 ATE336239 T1 AT E336239T1 AT 02024616 T AT02024616 T AT 02024616T AT 02024616 T AT02024616 T AT 02024616T AT E336239 T1 ATE336239 T1 AT E336239T1
Authority
AT
Austria
Prior art keywords
sub
hypertension
treatment
fatty acid
acid analogues
Prior art date
Application number
AT02024616T
Other languages
English (en)
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Application granted granted Critical
Publication of ATE336239T1 publication Critical patent/ATE336239T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT02024616T 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung des bluthochdrucks ATE336239T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS

Publications (1)

Publication Number Publication Date
ATE336239T1 true ATE336239T1 (de) 2006-09-15

Family

ID=19907879

Family Applications (5)

Application Number Title Priority Date Filing Date
AT99933293T ATE245416T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
AT02024388T ATE334666T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung der fettleber
AT02024616T ATE336239T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung des bluthochdrucks
AT99933292T ATE247464T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
AT99940723T ATE306916T1 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT99933293T ATE245416T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
AT02024388T ATE334666T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung der fettleber

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT99933292T ATE247464T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
AT99940723T ATE306916T1 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Country Status (17)

Country Link
US (4) US6365628B1 (de)
EP (5) EP1284139B1 (de)
JP (3) JP5057003B2 (de)
KR (3) KR100701502B1 (de)
CN (3) CN1223343C (de)
AT (5) ATE245416T1 (de)
AU (4) AU7240398A (de)
BR (2) BR9910297A (de)
CA (3) CA2331408C (de)
DE (5) DE69932864D1 (de)
DK (3) DK1075259T3 (de)
ES (3) ES2207253T3 (de)
NO (3) NO333143B1 (de)
NZ (3) NZ508047A (de)
PT (2) PT1075259E (de)
RU (3) RU2219920C2 (de)
WO (4) WO1999058120A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
EP1220669A4 (de) * 1999-10-13 2004-12-08 Marco A Chacon THERAPEUTISCHE MASSNAHME, UM DEN EFFEKT EINER KALORIENBESCHRäNKUNG NACHZUAHMEN
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20004844L (no) * 2000-09-27 2002-05-10 Thia Medica As Fettsyre analoger for behandling av proliferative hudsykdommer
NO20006008L (no) * 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
ES2359910T3 (es) * 2002-05-28 2011-05-30 Ajinomoto Co., Inc. Composición medicinal para inhibir la expresión de atp-citrato liasa y su uso.
EP1515978A1 (de) 2002-06-20 2005-03-23 IC Vec Limited Schwefelhaltige phospholipidderivate
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
PL377087A1 (pl) 2002-09-06 2006-01-23 Janssen Pharmaceutica, N.V. Związki heterocykliczne
AU2003272738B2 (en) * 2002-09-27 2010-04-01 Martek Biosciences Corporation Docosahexaenoic acid for improved glycemic control
ZA200502613B (en) * 2002-10-10 2006-10-25 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
AU2004212004B2 (en) * 2003-02-13 2008-01-10 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
BRPI0408490A (pt) * 2003-03-18 2006-04-04 Novartis Ag composições que compreendem ácidos graxos e aminoácidos
EP1718602A4 (de) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd Therapeutische und trägermoleküle
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
EP1761772A1 (de) * 2004-05-28 2007-03-14 Janssen Pharmaceutica N.V. Neue methode der arzneimittelverabreichung und blutentnahme in der nicht-betäubten ratte
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
RU2394598C2 (ru) * 2004-07-19 2010-07-20 Тиа Медика Ас Композиция, содержащая белковый материал и соединения, содержащие неокисляющиеся структурные элементы жирных кислот
AU2005264782B2 (en) * 2004-07-19 2010-12-16 Thia Medica As Composition comprising protein material and non-oxidizable fatty acid entities
RU2272628C1 (ru) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Способ быстрой оптимизации функций кровяных пластинок при метаболическом синдроме
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7288525B2 (en) * 2004-12-28 2007-10-30 The Research Foundation Of State University Of New York Method for lowering serum homocysteine
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
RU2441061C2 (ru) * 2005-05-04 2012-01-27 Пронова Биофарма Норге Эс. Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
WO2006117664A1 (en) * 2005-05-04 2006-11-09 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
EP2083817A4 (de) * 2006-10-20 2009-12-23 Cpd Llc Verfahren zur wiederherstellung der wirkung von incretin
CN101631757A (zh) * 2006-11-01 2010-01-20 普罗诺瓦生物医药挪威公司 ω-3脂质化合物
CA2667211A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
US7964751B2 (en) * 2007-02-26 2011-06-21 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
WO2008106091A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Use of long-chain alcohol derivatives for the treatment of alopecia areata
WO2009052182A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
US20100267828A1 (en) * 2007-10-31 2010-10-21 Anne Kristin Holmeide dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
WO2009132979A1 (en) * 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag 4-trimethylammonio-butyrates as cpt2 inhibitors
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (de) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Vorrichtung zur messung der konzentration eines gelösten stoffs und entsprechende verfahren
US8735436B2 (en) 2009-05-08 2014-05-27 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
WO2012016048A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti- viral azide-containing compounds
KR102265409B1 (ko) 2010-11-05 2021-06-16 바스프 에이에스 지질 화합물을 이용한 치료방법
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
AR094941A1 (es) 2013-02-28 2015-09-09 Olaf Hustvedt Svein Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y métodos para usarla
AU2014228387B2 (en) 2013-03-11 2016-09-01 Sciadonics, Inc. Lipid compositions containing bioactive fatty acids
HK1220606A1 (zh) 2013-03-11 2017-05-12 Nobesita As 包含非可氧化脂肪酸的天然脂类
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
EP3215154B1 (de) 2014-11-07 2020-01-29 Regents of the University of Minnesota Nützliche salze und zusammensetzungen zur behandlung von erkrankungen
CN115025079A (zh) 2015-04-28 2022-09-09 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
WO2019083816A1 (en) * 2017-10-23 2019-05-02 Epitracker, Inc. FATTY ACID ANALOGUES AND THEIR USE IN THE TREATMENT OF STATES RELATED TO METABOLIC SYNDROME
SG11202005007VA (en) 2017-12-06 2020-06-29 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
WO2020146263A1 (en) 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
EP4426130A1 (de) 2021-11-03 2024-09-11 Epitracker, Inc. Pentadecanoylcarnitin zur behandlung von alterungs- und langlebigkeitsbedingten leiden
KR20250043868A (ko) 2023-09-22 2025-03-31 건국대학교 산학협력단 옥시리핀을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
DE69622722T2 (de) * 1996-11-20 2003-02-27 N.V. Nutricia, Zoetermeer Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions

Also Published As

Publication number Publication date
KR20010043316A (ko) 2001-05-25
EP1285652B1 (de) 2006-08-16
DE69909775D1 (de) 2003-08-28
KR20010043315A (ko) 2001-05-25
DK1075259T3 (da) 2003-11-03
NZ508047A (en) 2003-05-30
CN1245157C (zh) 2006-03-15
CN1300212A (zh) 2001-06-20
CA2331395A1 (en) 1999-11-18
NO333143B1 (no) 2013-03-18
EP1075258B1 (de) 2003-08-20
AU5451799A (en) 1999-11-29
WO1999058123A2 (en) 1999-11-18
PT1075259E (pt) 2003-12-31
KR100701503B1 (ko) 2007-04-02
HK1034911A1 (en) 2001-11-09
DK1075258T3 (da) 2003-12-01
CA2331408C (en) 2008-10-21
NZ508045A (en) 2003-08-29
HK1034909A1 (en) 2001-11-09
US6417232B1 (en) 2002-07-09
CN1302204A (zh) 2001-07-04
NO20005461D0 (no) 2000-10-30
AU762790B2 (en) 2003-07-03
AU761355B2 (en) 2003-06-05
PT1075258E (pt) 2004-01-30
CA2331395C (en) 2008-10-14
NO20005461L (no) 2001-01-08
AU7240398A (en) 1999-11-29
RU2223095C2 (ru) 2004-02-10
ATE247464T1 (de) 2003-09-15
EP1075260A2 (de) 2001-02-14
DE69927805D1 (de) 2006-03-02
NZ508046A (en) 2003-08-29
US7026356B2 (en) 2006-04-11
EP1075258A1 (de) 2001-02-14
RU2221558C2 (ru) 2004-01-20
ATE334666T1 (de) 2006-08-15
CA2331393A1 (en) 1999-11-18
KR100701502B1 (ko) 2007-04-02
JP4465672B2 (ja) 2010-05-19
RU2219920C2 (ru) 2003-12-27
ES2251218T3 (es) 2006-04-16
JP5057003B2 (ja) 2012-10-24
DE69932645D1 (de) 2006-09-14
CA2331393C (en) 2009-08-11
WO1999058121A1 (en) 1999-11-18
US20020198259A1 (en) 2002-12-26
EP1075260B1 (de) 2005-10-19
HK1034912A1 (en) 2001-11-09
ES2204142T3 (es) 2004-04-16
DK1075260T3 (da) 2006-02-06
BR9910297A (pt) 2002-01-02
ES2207253T3 (es) 2004-05-16
DE69909775T2 (de) 2004-06-03
CA2331408A1 (en) 1999-11-18
EP1075259B1 (de) 2003-07-23
NO20005463D0 (no) 2000-10-30
JP2002514596A (ja) 2002-05-21
DE69910559T2 (de) 2004-06-17
WO1999058122A1 (en) 1999-11-18
CN1300211A (zh) 2001-06-20
JP2002514594A (ja) 2002-05-21
NO20005463L (no) 2001-01-08
WO1999058120A1 (en) 1999-11-18
BR9910296A (pt) 2002-01-15
EP1284139B1 (de) 2006-08-02
DE69927805T2 (de) 2006-07-06
US6365628B1 (en) 2002-04-02
AU762792B2 (en) 2003-07-03
AU4936699A (en) 1999-11-29
CN1223343C (zh) 2005-10-19
DE69910559D1 (de) 2003-09-25
KR100822077B1 (ko) 2008-04-14
WO1999058123A3 (en) 2000-03-09
EP1284139A1 (de) 2003-02-19
CN1244323C (zh) 2006-03-08
DE69932864D1 (de) 2006-09-28
ATE245416T1 (de) 2003-08-15
NO20005462D0 (no) 2000-10-30
AU4936799A (en) 1999-11-29
EP1075259A1 (de) 2001-02-14
NO20005462L (no) 2001-01-08
JP2002514595A (ja) 2002-05-21
KR20010043314A (ko) 2001-05-25
US6441036B1 (en) 2002-08-27
EP1285652A1 (de) 2003-02-26
ATE306916T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
ATE336239T1 (de) Neue fettsäureanaloge zur behandlung des bluthochdrucks
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
DE60133716D1 (de) Verwendungen eines getränks enthaltend ein polyphosphat zur behandlung von zahnerosionen
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
BR0212899A (pt) Compostos orgânicos
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
DK0865271T4 (da) Anvendelse af 2-ethylhexyl alfa-cyano-beta, beta-diphenylacrylat med henblik på at forbedre stabiliteten over for lys af p-methylbenzyliden-kamfer
ID27440A (id) Proses untuk menyiapkan penengah-penengah
DE60204014D1 (de) Chlormethylierung von thiophene
MXPA03010821A (es) Composiciones de aroma y fragancias.
BR0316971A (pt) Fenilalquinas
YU70799A (sh) Derivati tiazofurina
ATE327235T1 (de) 1,2,5,10-tetrahydropyridazino 4,5-böchinolin-1, 0-dione und ihre anwendung in der behandlung von schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties